Action Pharma Equity Group A/s - 0REU

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Dernier

0,40

Prix Achat

0,00

Prix Vente

0,00

Volume échangé

0,00

0,00 Fourchette du Jour 0,00

0,40 Plage de 52 semaines 0,40

Cap du marché

409,186M

Clôture Veille

0,40

Ouverture

Dernière Transaction

(O)

Dernière heure de transaction

Volume financier

VWAP

Volume moyen (3 m)

0,00

Actions en circulation

1 022 964 000

Rendement du Dividende

Ratio Cours sur Bénéfices

-16,60

Bénéfice par action (BPA)

-0,02

Chiffre d'affairess

Bénéfice net

-24,61M

Secteur

Investors, Nec

Industrie

Money Management

Site Web

www.blue-vision.dk

Siège social

Copenhagen, Dnk

Fondé

2002

Pharma Equity Group A/s est coté dans le secteur Investors de la London Stock Exchange avec le ticker 0REU. Le dernier cours de clôture d'Pharma Equity Group A/s était de kr0,40. Au cours de la dernière année, les actions de Pharma Equity Group A/s ont été négociées dans une fourchette de prix de kr 0,40 à kr 0,40.

Pharma Equity Group A/s compte actuellement 1 022 964 000 actions en circulation. La capitalisation boursière d'Pharma Equity Group A/s est de kr409,19 million. Pharma Equity Group A/s a un ratio cours/bénéfice (ratio PE) de -16.60.

Pharma Equity Group 2025 Financial Calendar

Pharma Equity Group 2025 Financial Calendar 14 January 2025 News Release Pharma Equity Group2025 Financial Calendar March 4Deadline for...

The Board of Directors' decision on a new execution strategy and prioritisation of clinical areas in Reponex Pharmaceuticals A/S.

The Board of Directors' decision on a new execution strategy and prioritisation of clinical areas in Reponex Pharmaceuticals A/S. The...

Martin Engell-Rossen will be Head of Cabinet to Denmark's new EU Commissioner Dan Jørgensen in Brussels and will therefore resign from the Board of Directors of Pharma Equity Group A/S

Martin Engell-Rossen will be Head of Cabinet to Denmark's new EU Commissioner Dan Jørgensen in Brussels and will therefore resign from the...

Consolidated Interim report 1 January – 30 September 2024

Consolidated Interim report 1 January – 30 September 2024 Consolidated Interim report 1 January – 30 September 2024 Company announcement no. 30 –...

Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has obtained patent protection in Japan for the treatment of colorectal cancer with RNX-051.

Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has obtained patent protection in Japan for the treatment of colorectal cancer...

Registration of capital reduction by way of a reduction of the nominal value and information on total share capital and number of voting rights

Registration of capital reduction by way of a reduction of the nominal value and information on total share capital and number of voting rights...

Période	Ouver.	Haut	Bas
1	0.4	0.4	0.4	DE
4	0.4	0.4	0.4	DE
12	0.4	0.4	0.4	DE
26	0.4	0.4	0.4	DE
52	0.4	0.4	0.4	DE
156	0.4	0.4	0.4	DE
260	0.4	0.4	0.4	DE

0REU - Frequently Asked Questions (FAQ)

What is the current Pharma Equity Group A/s share price?

The current share price of Pharma Equity Group A/s is kr 0,40

How many Pharma Equity Group A/s shares are in issue?

Pharma Equity Group A/s has 1 022 964 000 shares in issue

What is the market cap of Pharma Equity Group A/s?

The market capitalisation of Pharma Equity Group A/s is DKK 409,19M

What is the 1 year trading range for Pharma Equity Group A/s share price?

Pharma Equity Group A/s has traded in the range of kr 0,40 to kr 0,40 during the past year

What is the PE ratio of Pharma Equity Group A/s?

The price to earnings ratio of Pharma Equity Group A/s is -16,6

What is the reporting currency for Pharma Equity Group A/s?

Pharma Equity Group A/s reports financial results in DKK

What is the latest annual profit for Pharma Equity Group A/s?

The latest annual profit of Pharma Equity Group A/s is DKK -24,61M

What is the registered address of Pharma Equity Group A/s?

The registered address for Pharma Equity Group A/s is VESTER FARIMAGSGADE 1, 2, COPENHAGEN, DK-2900

What is the Pharma Equity Group A/s website address?

The website address for Pharma Equity Group A/s is www.blue-vision.dk

Which industry sector does Pharma Equity Group A/s operate in?

Pharma Equity Group A/s operates in the MONEY MANAGEMENT sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
SCGLSealand Capital Galaxy Limited	3,00p (40,19%)	5,3M
AGRAssura Plc	46,10p (18,21%)	20,76M
FXPOFerrexpo Plc	108,80p (12,86%)	2,1M
ONCOncimmune Holdings Plc	4,50p (12,50%)	136,61k
KDRKarelian Diamond Resources Plc	1,35p (10,20%)	502,54k
PDLPetra Diamonds Limited	23,90p (-17,59%)	469,08k
SYMESupply@me Capital Plc	0,0058p (-14,07%)	1,93B
CARCarclo Plc	20,00p (-13,79%)	179,93k
ESTEast Star Resources Plc	1,20p (-11,11%)	3M
WG.Wood Group (john) Plc	26,34p (-9,17%)	21,64M
SYMESupply@me Capital Plc	0,0058p (-14,07%)	1,93B
MSMNMosman Oil And Gas Limited	0,039p (0,00%)	174,31M
BZTBezant Resources Plc	0,024p (4,35%)	123,03M
CPXCap-xx Limited	0,1225p (0,00%)	107,04M
BCEBeacon Energy Plc	0,00425p (0,00%)	80,01M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Pharma Equity Group A/s (0REU)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

À propos de Pharma Equity Group A/s

0REU Dernières nouvelles

Pharma Equity Group 2025 Financial Calendar

The Board of Directors' decision on a new execution strategy and prioritisation of clinical areas in Reponex Pharmaceuticals A/S.

Martin Engell-Rossen will be Head of Cabinet to Denmark's new EU Commissioner Dan Jørgensen in Brussels and will therefore resign from the Board of Directors of Pharma Equity Group A/S

Consolidated Interim report 1 January – 30 September 2024

Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has obtained patent protection in Japan for the treatment of colorectal cancer with RNX-051.

Major shareholder announcement - Pharma Equity Group A/S

Managers’ transactions

Pharma Equity Group announces successful completion of directed issue of new shares

Pharma Equity Group announces issuance of new shares in a direct issue

Registration of capital reduction by way of a reduction of the nominal value and information on total share capital and number of voting rights

Pharma Equity Group 2025 Financial Calendar

The Board of Directors' decision on a new execution strategy and prioritisation of clinical areas in Reponex Pharmaceuticals A/S.

Martin Engell-Rossen will be Head of Cabinet to Denmark's new EU Commissioner Dan Jørgensen in Brussels and will therefore resign from the Board of Directors of Pharma Equity Group A/S

Consolidated Interim report 1 January – 30 September 2024

Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has obtained patent protection in Japan for the treatment of colorectal cancer with RNX-051.

Major shareholder announcement - Pharma Equity Group A/S

Managers’ transactions

Pharma Equity Group announces successful completion of directed issue of new shares

0REU - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Ouver.	Haut	Bas
1	0.4	0.4	0.4	DE
4	0.4	0.4	0.4	DE
12	0.4	0.4	0.4	DE
26	0.4	0.4	0.4	DE
52	0.4	0.4	0.4	DE
156	0.4	0.4	0.4	DE
260	0.4	0.4	0.4	DE

Période	Ouver.	Haut	Bas
1	0.4	0.4	0.4	DE
4	0.4	0.4	0.4	DE
12	0.4	0.4	0.4	DE
26	0.4	0.4	0.4	DE
52	0.4	0.4	0.4	DE
156	0.4	0.4	0.4	DE
260	0.4	0.4	0.4	DE

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Pharma Equity Group A/s (0REU) Cours

Pharma Equity Group A/s (0REU)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

À propos de Pharma Equity Group A/s

0REU Dernières nouvelles

Pharma Equity Group 2025 Financial Calendar

The Board of Directors' decision on a new execution strategy and prioritisation of clinical areas in Reponex Pharmaceuticals A/S.

Martin Engell-Rossen will be Head of Cabinet to Denmark's new EU Commissioner Dan Jørgensen in Brussels and will therefore resign from the Board of Directors of Pharma Equity Group A/S

Consolidated Interim report 1 January – 30 September 2024

Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has obtained patent protection in Japan for the treatment of colorectal cancer with RNX-051.

Major shareholder announcement - Pharma Equity Group A/S

Managers’ transactions

Pharma Equity Group announces successful completion of directed issue of new shares

Pharma Equity Group announces issuance of new shares in a direct issue

Registration of capital reduction by way of a reduction of the nominal value and information on total share capital and number of voting rights

Pharma Equity Group 2025 Financial Calendar

The Board of Directors' decision on a new execution strategy and prioritisation of clinical areas in Reponex Pharmaceuticals A/S.

Martin Engell-Rossen will be Head of Cabinet to Denmark's new EU Commissioner Dan Jørgensen in Brussels and will therefore resign from the Board of Directors of Pharma Equity Group A/S

Consolidated Interim report 1 January – 30 September 2024

Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has obtained patent protection in Japan for the treatment of colorectal cancer with RNX-051.

Major shareholder announcement - Pharma Equity Group A/S

Managers’ transactions

Pharma Equity Group announces successful completion of directed issue of new shares

0REU - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Ouver.	Haut	Bas
1	0.4	0.4	0.4	DE
4	0.4	0.4	0.4	DE
12	0.4	0.4	0.4	DE
26	0.4	0.4	0.4	DE
52	0.4	0.4	0.4	DE
156	0.4	0.4	0.4	DE
260	0.4	0.4	0.4	DE